Transatlantic Tremors: How US Drug Pricing Reforms Are Reshaping the Global Pharmaceutical Landscape

Trump's Bold Vision: Pushing for Direct Drug Deals to Slash Costs

AstraZeneca's Bold Leap: Simplifying US Investment with a Direct Nasdaq Listing

AstraZeneca's Bold Leap: Transforming Patient Access with New Direct-to-Consumer Platform

Historic Shift: White House Reviews Landmark Drug Price Negotiation Rule

European Experts Back Two AstraZeneca Breakthroughs: New Hope for Rare Diseases

Trump's Biotech Revolution: Unleashing a Staggering $350 Billion Investment Wave

AstraZeneca's Baxdrostat: A Beacon of Hope in the Fight Against Uncontrolled High Blood Pressure

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

First RSV shots, groundbreaking gene therapy among 2024 drugs to watch